Several other studies also support the use of Truvada
for HIV risk reduction.
The FDA has also recommended Truvada
be taken with existing antiretroviral drugs for people who have been diagnosed with HIV.
However, official FDA backing of its use as a preventative practice would allow Truvada
's maker, Gilead Sciences Inc, to market it for that purpose.
"We have tools that when combined are going to allow us to break the back of the epidemic." Doctors would be able to prescribe Truvada
for prevention without regulatory approval.
A total of 2,499 participants from the US, Peru, Ecuador, Brazil, South Africa and Thailand were randomly assigned to take Truvada
on a daily basis or an inactive dummy placebo pill.
Gilead Sciences Inc chief executive John Martin holds a Truvada
Drug resistance is also an unknown if one partner becomes exposed to HIV after taking Truvada
sales were $516.1 million for the second quarter of 2008, an increase of 34 percent from $385.4 million in the second quarter of 2007.
Cohen: In as statement on August 26, 2004, Gilead released early (24 week) results of a study comparing the Truvada
drugs with Combivir (the other drug was Sustiva in both cases).
Results from the DISCOVER trial demonstrated that Descovy achieved non-inferiority to Truvada
in study participants who were at substantial and sustained risk of HIV acquisition.
Ocasio-Cortez expressed outrage the prescription combination drug Truvada
(Emtricitabine / Tenofovir Disoproxil Fumarate), which was developed with U.S.